Kara L Kliewer, Cristin Murray-Petzold, Margaret H Collins, Juan P Abonia, Scott M Bolton, Lauren A DiTommaso, Lisa J Martin, Xue Zhang, Vincent A Mukkada, Philip E Putnam, Erinn S Kellner, Ashley L Devonshire, Justin T Schwartz, Vidhya A Kunnathur, Chen E Rosenberg, John L Lyles, Tetsuo Shoda, Amy D Klion, Marc E Rothenberg
BACKGROUND: In eosinophilic gastrointestinal diseases, the role of eosinophils in disease pathogenesis and the effect of eosinophil depletion on patient outcomes are unclear. Benralizumab, an eosinophil-depleting monoclonal antibody that targets the interleukin-5 receptor α, might eliminate gastric tissue eosinophils and improve outcomes in eosinophilic gastritis. We aimed to assess the efficacy and safety of benralizumab in patients with eosinophilic gastritis. METHODS: We conducted a single-site, randomised, double-blind, placebo-controlled, phase 2 trial at Cincinnati Children's Hospital Medical Center (Cincinnati, OH, USA)...
September 2023: Lancet. Gastroenterology & Hepatology